contract research organization

AnaBios Corporation provides human-based drug response profiles in advance of clinical trials. AnaBios’ Phase X™ (human tissue-based ex-vivo drug development studies) enables decision making concerning compound selection, dosing, risk mitigation and management. The Phase X™ studies allow pharmaceutical companies to efficiently advance their drug development programs with a greater degree of confidence at a fraction of the cost and with accelerated timelines compared to current development paradigms.